Penn Medicine: Immunotherapy drug pembrolizumab shows promise for mesothelioma patients

(University of Pennsylvania School of Medicine) The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall, according to a new study from researchers in the Perelman School of Medicine at the University of Pennsylvania.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news